Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -95.47 Million USD | 57.81% |
| 2022 | -226.85 Million USD | 34.79% |
| 2021 | -347.86 Million USD | -69.74% |
| 2020 | -204.94 Million USD | -111.48% |
| 2019 | -96.91 Million USD | -556.79% |
| 2018 | 21.21 Million USD | -18.78% |
| 2017 | 26.12 Million USD | -0.18% |
| 2016 | 26.17 Million USD | 49.51% |
| 2015 | 17.5 Million USD | 183.47% |
| 2014 | 6.17 Million USD | 2.92% |
| 2013 | 6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -87.55 Million USD | 0.0% |
| 2024 Q1 | -87.55 Million USD | -4512.94% |
| 2023 Q2 | -93.57 Million USD | -100.0% |
| 2023 Q1 | -46.79 Million USD | 51.23% |
| 2023 FY | -95.7 Million USD | 57.81% |
| 2023 Q4 | -1.89 Million USD | -100.22% |
| 2023 Q3 | -948 Thousand USD | 98.99% |
| 2022 Q3 | -45.67 Million USD | 65.08% |
| 2022 Q2 | -130.8 Million USD | -93.06% |
| 2022 Q1 | -67.75 Million USD | 73.56% |
| 2022 FY | -226.85 Million USD | 34.79% |
| 2022 Q4 | -95.93 Million USD | -110.05% |
| 2021 Q4 | -256.26 Million USD | -91.53% |
| 2021 Q1 | -45.56 Million USD | 50.38% |
| 2021 FY | -347.86 Million USD | -69.74% |
| 2021 Q3 | -133.79 Million USD | -46.91% |
| 2021 Q2 | -91.06 Million USD | -99.89% |
| 2020 Q4 | -91.82 Million USD | -99.93% |
| 2020 Q2 | -113.24 Million USD | -100.27% |
| 2020 Q1 | -56.54 Million USD | 19.09% |
| 2020 FY | -204.94 Million USD | -111.48% |
| 2020 Q3 | -45.92 Million USD | 59.45% |
| 2019 Q3 | -34.78 Million USD | -26.7% |
| 2019 Q4 | -69.88 Million USD | -100.92% |
| 2019 FY | -96.91 Million USD | -556.79% |
| 2019 Q1 | -13.67 Million USD | -580.01% |
| 2019 Q2 | -27.45 Million USD | -100.78% |
| 2018 Q3 | 2.84 Million USD | -63.29% |
| 2018 Q2 | 7.75 Million USD | 0.0% |
| 2018 Q4 | 2.84 Million USD | 0.0% |
| 2018 Q1 | 7.75 Million USD | 39.27% |
| 2018 FY | 21.21 Million USD | -18.78% |
| 2017 Q3 | 5.57 Million USD | -25.61% |
| 2017 FY | 26.12 Million USD | -0.18% |
| 2017 Q4 | 5.57 Million USD | 0.0% |
| 2017 Q2 | 7.49 Million USD | 0.0% |
| 2017 Q1 | 7.49 Million USD | 15.42% |
| 2016 Q1 | 6.59 Million USD | 12.19% |
| 2016 FY | 26.17 Million USD | 49.51% |
| 2016 Q4 | 6.48 Million USD | 0.0% |
| 2016 Q3 | 6.48 Million USD | -1.61% |
| 2016 Q2 | 6.59 Million USD | 0.0% |
| 2015 Q3 | 5.87 Million USD | 104.63% |
| 2015 Q1 | 2.87 Million USD | 169.89% |
| 2015 Q4 | 5.87 Million USD | 0.0% |
| 2015 FY | 17.5 Million USD | 183.47% |
| 2015 Q2 | 2.87 Million USD | 0.0% |
| 2014 Q1 | 2.02 Million USD | 0.0% |
| 2014 FY | 6.17 Million USD | 2.92% |
| 2014 Q4 | 1.06 Million USD | 0.0% |
| 2014 Q3 | 1.06 Million USD | -47.38% |
| 2014 Q2 | 2.02 Million USD | 0.0% |
| 2013 FY | 6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -7049.527% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1267.31% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 280.217% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4473.35% |
| Rebus Holdings, Inc. | -1.02 Million USD | -9260.49% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 246.588% |
| Qrons Inc. | -789.34 Thousand USD | -11995.694% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -14997.398% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -52.522% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -22879.982% |
| Skye Bioscience, Inc. | -37.64 Million USD | -153.626% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -27.366% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1351.876% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -34821.837% |
| SQZ Biotechnologies Company | -79.46 Million USD | -20.151% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -3200.968% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -5144.468% |
| Mesoblast Limited | -87.95 Million USD | -8.551% |
| Marizyme, Inc. | -65.34 Million USD | -46.108% |
| Genus plc | 7.9 Million USD | 1308.57% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -776.6% |
| Pharming Group N.V. | -10.54 Million USD | -805.167% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -4300.239% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2473.342% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -979.568% |
| ContraFect Corporation | -65.15 Million USD | -46.543% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1854.068% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -5427.033% |
| IMV Inc. | -36.48 Million USD | -161.683% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1084.625% |
| MultiCell Technologies, Inc. | -380.07 USD | -25120798.782% |
| ONE Bio Corp. | 8.67 Million USD | 1200.395% |
| Accustem Sciences Inc. | -3.74 Million USD | -2448.487% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -84.704% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -7434.878% |
| Q BioMed Inc. | -2.05 Million USD | -4552.664% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2457.648% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -3910.173% |
| Biomind Labs Inc. | -1.21 Million USD | -7762.596% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -59.86% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2978.148% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1108.097% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -4798.143% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -637433.387% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -501.565% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1541.273% |
| GB Sciences, Inc. | -1.36 Million USD | -6911.722% |
| Alpha Cognition Inc. | -13.77 Million USD | -593.24% |
| HST Global, Inc. | -146.21 Thousand USD | -65201.279% |
| CSL Limited | 2.64 Billion USD | 103.614% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -5340.995% |
| Halberd Corporation | -79.67 Thousand USD | -119731.568% |
| Enzolytics Inc. | -2.17 Million USD | -4286.053% |
| Agentix Corp. | -1.37 Million USD | -6847.769% |
| Resverlogix Corp. | -3.61 Million USD | -2544.792% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -2910.529% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 67.641% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 97525.51% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1478.81% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2303.15% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -3055.081% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1388.654% |
| Zenith Capital Corp. | -10.59 Million USD | -801.066% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -410695.112% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2202.906% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -157868.293% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4661.672% |
| Kadimastem Ltd | -3.3 Million USD | -2786.771% |
| Helix BioMedix, Inc. | -1.05 Million USD | -8940.895% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2400.052% |
| BioStem Technologies, Inc. | -8.48 Million USD | -1025.512% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -21532.013% |
| LadRx Corporation | 400.44 Thousand USD | 23942.844% |
| Cell Source, Inc. | -5.32 Million USD | -1694.272% |
| Regen BioPharma, Inc. | 1.02 Million USD | 9428.408% |
| Regen BioPharma, Inc. | 1.02 Million USD | 9428.408% |
| NovAccess Global Inc. | -4.76 Million USD | -1901.955% |
| Affymax, Inc. | -14.42 Million USD | -561.932% |
| Itoco Inc. | -1.86 Million USD | -5008.467% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -2049.156% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -5620.611% |
| Mobile Lads Corp. | -2.26 Million USD | -4118.501% |
| CytoDyn Inc. | -49.84 Million USD | -91.563% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -120706.499% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -41752.565% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -10040.633% |
| SYBLEU INC | -180.3 Thousand USD | -52853.345% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -5820.184% |
| International Stem Cell Corporation | -131 Thousand USD | -72783.206% |
| Bioxytran, Inc. | -4.28 Million USD | -2130.77% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -175823.128% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -3673.426% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -98.612% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4416.414% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -12126.737% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -2913.794% |
| Neutra Corp. | -233.46 Thousand USD | -40795.637% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -370.539% |
| PureTech Health plc | -65.69 Million USD | -45.329% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -348.954% |
| IXICO plc | -1.17 Million USD | -8005.008% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -861.791% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -67.128% |
| CSL Limited | 2.64 Billion USD | 103.614% |
| Cellectis S.A. | -103.17 Million USD | 7.46% |